BACKGROUND AND AIM: Hepatitis C virus (HCV) has been postulated to be an etiological agent for lymphoid malignancies. Whereas a high prevalence of HCV infection in non-Hodgkin's lymphoma (NHL) patients has been shown to exist in many geographical areas of high HCV prevalence, studies from other parts have not established any form of association. In India, there is a scarcity of data to show either a positive or a negative association between NHL and HCV infection. Therefore, we determined the prevalence of HCV infection in patients with NHL. METHODS: A total of 228 subjects were included, out of which, the number of newly diagnosed consecutive patients with lymphoproliferative disorders (NHL and CLL) were 57 [mean age, 48.7 years (range: 18-80)] and the control group consisted of 171 subjects [mean age, 48.6 years (range: 18-80)]. We used third generation enzyme immunoassay to detect HCV antibodies. HCV RNA was detected by nested RT-PCR. RESULTS: Among the 57 patients of NHL, 44 (77.2%) had high-grade disease (diffuse large B cell), 6 (10.5%) intermediate-grade (follicular lymphoma), and 7 (12.3%) low-grade (small lymphocytic); 26 patients had B symptoms at diagnosis. None of the patient tested positive for antibody to hepatitis C virus (anti-HCV) while 1 patient (1.75%) tested positive for HCV RNA. Among the age- and sex- matched controls, 2 (1.17%) subjects tested positive for anti-HCV; both were also positive for HCV RNA. CONCLUSIONS: HCV infection is unlikely to be associated with lymphoproliferative disorders in northern India and does not play a major role in the pathogenesis of lymphoproliferative disorders.
BACKGROUND AND AIM: Hepatitis C virus (HCV) has been postulated to be an etiological agent for lymphoid malignancies. Whereas a high prevalence of HCV infection in non-Hodgkin's lymphoma (NHL) patients has been shown to exist in many geographical areas of high HCV prevalence, studies from other parts have not established any form of association. In India, there is a scarcity of data to show either a positive or a negative association between NHL and HCV infection. Therefore, we determined the prevalence of HCV infection in patients with NHL. METHODS: A total of 228 subjects were included, out of which, the number of newly diagnosed consecutive patients with lymphoproliferative disorders (NHL and CLL) were 57 [mean age, 48.7 years (range: 18-80)] and the control group consisted of 171 subjects [mean age, 48.6 years (range: 18-80)]. We used third generation enzyme immunoassay to detect HCV antibodies. HCV RNA was detected by nested RT-PCR. RESULTS: Among the 57 patients of NHL, 44 (77.2%) had high-grade disease (diffuse large B cell), 6 (10.5%) intermediate-grade (follicular lymphoma), and 7 (12.3%) low-grade (small lymphocytic); 26 patients had B symptoms at diagnosis. None of the patient tested positive for antibody to hepatitis C virus (anti-HCV) while 1 patient (1.75%) tested positive for HCV RNA. Among the age- and sex- matched controls, 2 (1.17%) subjects tested positive for anti-HCV; both were also positive for HCV RNA. CONCLUSIONS:HCV infection is unlikely to be associated with lymphoproliferative disorders in northern India and does not play a major role in the pathogenesis of lymphoproliferative disorders.
Authors: E Zuckerman; T Zuckerman; A M Levine; D Douer; K Gutekunst; M Mizokami; D G Qian; M Velankar; B N Nathwani; T L Fong Journal: Ann Intern Med Date: 1997-09-15 Impact factor: 25.391
Authors: M Kuniyoshi; M Nakamuta; H Sakai; M Enjoji; N Kinukawa; K Kotoh; M Fukutomi; M Yokota; H Nishi; H Iwamoto; N Uike; J Nishimura; S Inaba; Y Maeda; H Nawata; K Muta Journal: J Gastroenterol Hepatol Date: 2001-02 Impact factor: 4.029
Authors: Silvia de Sanjose; Yolanda Benavente; Claire M Vajdic; Eric A Engels; Lindsay M Morton; Paige M Bracci; John J Spinelli; Tongzhang Zheng; Yawei Zhang; Silvia Franceschi; Renato Talamini; Elizabeth A Holly; Andrew E Grulich; James R Cerhan; Patricia Hartge; Wendy Cozen; Paolo Boffetta; Paul Brennan; Marc Maynadié; Pierluigi Cocco; Ramon Bosch; Lenka Foretova; Anthony Staines; Nikolaus Becker; Alexandra Nieters Journal: Clin Gastroenterol Hepatol Date: 2008-04 Impact factor: 11.382
Authors: Claudia Schöllkopf; Karin Ekström Smedby; Henrik Hjalgrim; Klaus Rostgaard; Inge Panum; Lasse Vinner; Ellen T Chang; Bengt Glimelius; Anna Porwit; Christer Sundström; Mads Hansen; Hans-Olov Adami; Mads Melbye Journal: Int J Cancer Date: 2008-04-15 Impact factor: 7.396
Authors: Vahap Okan; Mehmet Yilmaz; Aysen Bayram; Cem Kis; Sami Cifci; Hakan Buyukhatipoglu; Mustafa Pehlivan Journal: Int J Hematol Date: 2008-10-04 Impact factor: 2.490
Authors: Mehmet Sonmez; Ozlen Bektas; Mustafa Yilmaz; Ahmet Durmus; Elif Akdogan; Murat Topbas; Murat Erturk; Ercument Ovali; Serdar Bedii Omay Journal: Tumori Date: 2007 Nov-Dec
Authors: Gerald Y Minuk; Betty Lerner; Spencer B Gibson; James B Johnston; Julia Uhanova; Anton Andonov; Jun Wu Journal: Can J Gastroenterol Hepatol Date: 2014-03